Biopharma companies may need to transfer production projects to other manufacturing sites multiple times across the lifecycle of a medicine. Moving between sites enables companies to access the facilities that are the best current fit for a drug candidate or product, rather than being tied to capacity that is no longer ideal. However, the transfer process can also be a source of risks that must be managed and mitigated. Both types of transfers, tech transfer and site transfer, pose a wide range of challenges that companies need to identify and address to minimize risks.
In this white paper, we discuss how Piramal Pharma Solutions has both the capabilities to identify and mitigate risks and the broad global network of manufacturing facilities needed to provide partners with the right site for products at every stage of the life cycle. Piramal’s facilities in the US and have teams experienced in moving drugs between sites, thereby simplifying tech and site transfers and mitigating all the risks they can entail.
